Respiratorius
1.29 SEK
-6.86 %
Less than 1K followers
RESP
Spotlight Stock Market
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-6.86 %
-14.29 %
-20.37 %
-34.52 %
-65.32 %
-82.57 %
-97.19 %
-98.86 %
-90.98 %
Respiratorius is a research company focused on the development of drug candidates for the treatment of cancer, and especially aggressive lymphoma. The company was established in 1999 as a spin-off from Lund University. The operations are located in Sweden, where research is conducted in-house, but also through international partners. The company has its headquarters in Lund.
Read moreMarket cap
10.19M SEK
Turnover
53.72K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
26.5
2026
Interim report Q1'26
9.6
2026
General meeting '26
11.8
2026
Interim report Q2'26
All
Press releases
ShowingAll content types
Respiratorius has conducted a pre-IND meeting with the FDA
Respiratorius Granted Pre-IND Meeting with FDA for VAL001
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools